Read this first
This is plain-language harm-reduction information, not medical advice. Peptides discussed here are research compounds; most are not approved for human use. People will use them either way — we would rather they have the facts.
What it is
KPV is the three-amino-acid tail of α-MSH (alpha melanocyte-stimulating hormone), and it retains the anti-inflammatory effects of the parent peptide without the pigmentation effects.
It has been studied for inflammatory bowel disease, skin inflammation and wound healing.
History
Identified as the active anti-inflammatory fragment of α-MSH in the 1990s.
How it works
Reduces inflammation by suppressing NF-kB signalling — a master regulator of inflammatory gene expression — in immune cells and gut epithelium.
Dosage
- Subcutaneous: 200–500 mcg daily.
- Oral: 250–500 mcg daily (used for gut-specific applications).
How it is taken
- Subcutaneous injection, oral capsule, or topical for skin inflammation.
How to reconstitute
- 5 mg vial with 2 ml BAC water = 2.5 mg/ml. 250 mcg = 10 units on a 1 ml insulin syringe.
How it should arrive
White powder, sealed vial.
How it should look once reconstituted
Clear colourless solution.
What to expect, and when
- Gut symptom changes: 1–3 weeks.
- Skin inflammation: 2–6 weeks.
Side effects
- Generally well tolerated.
- Mild injection-site reactions.
Risks
- Limited human data.
- Suppressing inflammation systemically is not always desired.
Potential gains
- Gut inflammation reduction (IBD-style symptoms).
- Skin inflammation reduction (eczema, psoriasis support).
Other useful information
Often stacked with BPC-157 for gut healing protocols.
Looking for a goal-based recommendation?
Try the Find your goal tool — answer five short questions and get peptides matched to what you actually want.